Filing Details
- Accession Number:
- 0001999371-25-004117
- Form Type:
- 13G Filing
- Publication Date:
- 2025-04-09 20:00:00
- Filed By:
- Affinity Healthcare Fund, LP
- Company:
- Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
- Filing Date:
- 2025-04-10
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Beneficially Owned Number of Shares | Beneficially Owned Number of Aggregate Shares | Percent of Class |
|---|---|---|---|
| Affinity Healthcare Fund, LP | 0 | 664,224 | 7.83% |
| Affinity Asset Advisors, LLC | 0 | 664,224 | 7.83% |
Filing
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
Karyopharm Therapeutics Inc. (Name of Issuer) |
Common Stock, par value $0.0001 per share (Title of Class of Securities) |
48576U205 (CUSIP Number) |
04/03/2025 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
 Rule 13d-1(c)
|
| Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. | 48576U205 |
| 1 | Names of Reporting Persons
Affinity Healthcare Fund, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
664,224.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
7.83 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13G
|
| CUSIP No. | 48576U205 |
| 1 | Names of Reporting Persons
Affinity Asset Advisors, LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
664,224.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
7.83 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IA |
SCHEDULE 13G
|
| Item 1. | ||
| (a) | Name of issuer:
Karyopharm Therapeutics Inc. | |
| (b) | Address of issuer's principal executive offices:
85 Wells Avenue, 2nd Floor, Newton, MA 02459 | |
| Item 2. | ||
| (a) | Name of person filing:
Affinity Healthcare Fund, LP
Affinity Asset Advisors, LLC | |
| (b) | Address or principal business office or, if none, residence:
450 Park Avenue
Suite 1403
New York, NY 10022 | |
| (c) | Citizenship:
Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC - Delaware | |
| (d) | Title of class of securities:
Common Stock, par value $0.0001 per share | |
| (e) | CUSIP No.:
48576U205 | |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| (a) | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
| |
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
| |
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
| |
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
| |
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
| |
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
| |
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
| |
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
| |
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
| |
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: | |
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
| |
| Item 4. | Ownership | |
| (a) | Amount beneficially owned:
Affinity Asset Advisors, LLC (the "Advisor") is the investment manager of Affinity Healthcare Fund, LP (the "Fund") and exercises investment discretion with regard to the securities reported herein. As of April 10, 2025, the Fund beneficially owned an aggregate of 664,224 shares of Common Stock of the Issuer, or 7.83% of the outstanding shares of Common Stock of the Issuer, and the Advisor may be deemed to be the beneficial owner of such 664,224 shares of Common Stock of the Issuer owned by the Fund by virtue of its position as investment manager of the Fund. The Fund and the Advisor have the shared power to vote or to direct the vote and to dispose or direct the disposition of 664,224 shares of Common Stock of the Issuer. The shares beneficially owned by the Fund represent (a) 600,100 shares of Common Stock of the Issuer which may be acquired upon exercise of certain equity call options held by the Fund and (b) 64,124 shares of Common Stock of the Issuer which may be acquired upon conversion of the Issuer's Convertible Bond due 10/15/25 held by the Fund. | |
| (b) | Percent of class:
The percentage set forth in Item 4(a) and in Row 11 of the cover page for each reporting person is based on 8,480,170 shares of Common Stock of the Issuer outstanding as of February 24, 2025 as set forth in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 19, 2025 after giving effect to the Reverse Stock Split effected pursuant to an amendment to the Issuer's Restated Certificate of Incorporation filed on February 24, 2025 as reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2025 and including the shares issuable upon conversion of the Convertible Bond referred to in Item 4(a). | |
| (c) | Number of shares as to which the person has:
| |
| (i) Sole power to vote or to direct the vote:
Affinity Asset Advisors, LLC 0 shares of Common Stock
Affinity Healthcare Fund, LP 0 shares of Common Stock | ||
| (ii) Shared power to vote or to direct the vote:
Affinity Asset Advisors, LLC 664,224 shares of Common Stock
Affinity Healthcare Fund, LP 664,224 shares of Common Stock | ||
| (iii) Sole power to dispose or to direct the disposition of:
Affinity Asset Advisors, LLC 0 shares of Common Stock
Affinity Healthcare Fund, LP 0 shares of Common Stock | ||
| (iv) Shared power to dispose or to direct the disposition of:
Affinity Asset Advisors, LLC 664,224 shares of Common Stock
Affinity Healthcare Fund, LP 664,224 shares of Common Stock | ||
| Item 5. | Ownership of 5 Percent or Less of a Class. | |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
| Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
| Item 9. | Notice of Dissolution of Group. | |
Not Applicable
| ||
| Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|